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Malignancy diagnosed during pregnancy is a rare coincidence and a taxing situation for the health care provider. The diagnosis 
and therapeutic management become laborious and it involves both the mother and fetus. One of the major cause of death 
among women of the childbearing age group is malignant melanoma in the western world. The literature vastly suggests 
that it has an ominous prognosis when diagnosed during pregnancy as it is known to rapidly metastasize to the placenta 
and fetus. Prompt diagnosis and appropriate treatment can avoid catastrophic events. We report a case of Indian women 
diagnosed with non‑ metastatic malignant melanoma in the first trimester of pregnancy with successful outcome.
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Introduction
Cancer incidence during pregnancy is estimated to be 
around 1/1000.[1] Malignant melanoma (MM) was considered 
an aggressive malignancy during pregnancy accounting to 
8% of all malignancies occurring when pregnant.[2] Despite 
disparate experiences published over the years on melanoma 
during pregnancy, recent data suggest a general agreement 
that pregnancy does not affect the outcome. Furthermore, 
there are no definite guidelines or consensus as there 
is little quality research in this field. The diagnosis and 
management of such cases is a delicate affair with ethical 
and psychological considerations. An assessment of the risk–
benefit ratio for diagnostic work-up, surgery, chemotherapy, 
and radiotherapy must be carried out. Timely diagnosis 
during pregnancy has been reported toward a favorable 
maternal and fetal outcome as in this case. Interdisciplinary 
team approach is imperative for such cases to provide an 
effective and efficient care. Here, MM diagnosed at first 
trimester with a successful maternal–fetal outcome is 
presented.
Case Report
A 34-year-old healthy primigravida of 12 weeks gestation, 
married for 9 years, had presented to us with verrucous 
posterior auricular lesion of 4 months duration, gradually 
increasing in size. The patient did not report any other illness 
and had not taken any medications. On examination, she had 
a 5 cm × 5 cm hemispherical posterior auricular mass, hard 
in consistency, well-defined borders, and irregular surface 
with no ulceration or bleeding with palpable hard mobile 
neck nodes. An edge biopsy of the lesion was performed 
and histological examination described it as MM Clark level 
IV as the tumor cells were seen in deep dermis with no 
subcutaneous tissue involvement with no junctional activity 
in the overlying skin. Magnetic resonance imaging (MRI) of 
the brain and neck revealed erosion of the underlying mastoid 
bone with a large exophytic lesion in the left occipitalis muscle 
and bilateral subcentimeter lymph nodes involvement in level 
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1A, 1B, 2A, 2B, and left-sided 5A node. Abdominal ultrasound 
showed no evidence of metastasis. Chest radiography was 
circumvented due to her early gestational age and as there 
were no clinical evidence of metastasis. Target scan was 
done and anomalies were ruled out. A team comprising the 
obstetrician, surgeon, oncologist, and plastic surgeon were 
consulted, and after a consensus on the treatment, she 
underwent wide local excision with left modified radical neck 
dissection with transposition flap reconstruction at 22 weeks 
of gestation, histology of which revealed it to be an invasive 
nodular MM with margins free of tumor, stage T4N1M0. 
Since then, the patient was followed up carefully, antenatal 
period was uneventful, and at the 38th week of gestation 
she delivered a healthy 3.360-kg girl baby with an Apgar 
of 8/10 9/10 by emergency lower segment cesarean section 
due to severe oligohydramnios. The placenta examined 
was grossly normal and pathology revealed no metastasis. 
She has been disease-free for 6 months post-partum now. 
Figure 1 comprises of images of this indexed case.
Discussion
MM is one of the commonest malignancy reported during 
the childbearing age group with an incidence ranging from 
0.14 to 2.8 per 1,000 live births;[2] however, its incidence 
among the dark skinned race is fewer in number.[3] As there is 
a demographic age shift toward later conception, increasing 
into the third and fourth decades of life, more and more cases 
are being reported during pregnancy.
Traditionally, from anecdotal reports it is suggested that 
MM is a rapidly growing malignancy which can potentially 
metastasize to the fetus and placenta when it occurs during 
pregnancy with unfavorable prognosis and that surgical 
sterilization should be opted.[4] However, recent studies do 
not support these data and state that there are no differences 
between the overall survival especially when diagnosed at 
an earlier stage.[5,6] During hormonal replacement therapy 
and pregnancy, there is increased pigmentation in different 
parts of the body; however, they do not seem to promote 
melanoma. And it has been proved that although melanomas 
are hormone-sensitive tumors, there are no estrogen 
receptors in the melanoma cells.[7]
As per the studies conducted by Lens et al. and O’Meara 
et al., there was no significant increase in morbidity or 
the prognosis of women diagnosed with non-metastatic 
melanoma and that pregnancy is not associated with 
worsening of survival by upgrading the disease.[8,9] However, 
Slingluff et al. found shorter disease-free interval as a result of 
decreased duration of nodal metastasis on pregnant women 
with metastatic melanoma.[10] Johansson et al. have reported 
no significant difference in mortality when a group of women 
diagnosed with melanoma during pregnancy were compared 
with women diagnosed with melanoma who did not become 
pregnant during a comparable period of time.[11] Although 
there are several conflicting reports from all over the world, 
the literature vastly suggest that patients who are pregnant 
at the time of diagnosis have a poorer prognosis than women 
who are not pregnant.[12]
Pregnancy associated with MM should be considered as 
a high-risk pregnancy, requiring interdisciplinary team 
approach with fetal monitoring and Doppler study is 
mandatorily throughout. MRI is a safe modality and should 
be used in staging of the disease. There are several reports 
of cases where early medical attention was not sought or 
they were missed diagnosed at an early stage due to the low 
index of suspicion during pregnancy, leading to metastasis 
and ultimately morbidity; however, as in this indexed report 
early recognition and prompt surgical management result in 
a favorable outcome.[13]
Nikolin and Sveljo in their study published 87 cases of 
placental and fetal involvement with maternal malignancies. 
Of these, 72 (83%) reported placental involvement only and 
5 (6%) reported both placental and fetal metastasis.[14] The 
review of literature also states that male infants are at a higher 
risk of developing metastasis from maternal malignancy 
compared with females.[12,14] Neonates who develop clinical 
evidence of metastasis carry a grave prognosis with mortality 
occurring within 3 months from diagnosis; on the other 
hand, infants who have no clinical evidence of the disease 
but with placental involvement need to be considered as a 
high-risk group and must be periodically evaluated for at 
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The management of melanoma involves diff icult 
decision-making as it involves both the mother and fetus. 
Maternal counseling is of paramount importance, and 
providing emotional and psychological support and care to 
such mothers is a challenge to every healthcare provider. The 
treatment options are similar in pregnant and non-pregnant 
women, and it is based on the stage of the disease. Surgery 
is the definitive treatment of early-stage melanoma; but for 
metastatic disease, the initiation of chemotherapeutic agents 
is still a dilemma, although several agents can be used in 
pregnancy without much harm to the fetus after the period 
of organogenesis;[16] however, these agents should not be 
given in the first trimester unless unavoidable. There have 
been no published data on the increased risk of perinatal 
adverse outcome such as preterm birth, low birth weight, or 
congenital defects. Future pregnancy need not be delayed 
in case of localized disease; however, literature suggests a 
recurrence-free time period of 2–3 years interval in advanced 
disease.
This reported case supports the fact that pregnancy does 
not worsen the progression of the disease especially when 
diagnosed at an earlier stage.
Conclusion
On the basis of the limited recent studies and this indexed 
report, pregnancy does not appear to have any influence 
on the prognosis of MM and that there is no evidence to 
postpone or terminate pregnancy especially when diagnosed 
in an early-stage disease. The main objective of this report is 
to enlighten the obstetricians the need for multidisciplinary 
team approach for such cases, vigilant examination of 
pigmented lesions during pregnancy, and that it should not 
be always considered as physiological. Early diagnosis with a 
biopsy and prompt treatment as in this case would improve 
the prognosis of these patients and avoid catastrophic 
outcome.
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